Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Biomedrex Genetics

Main focus: Next-generation CRISPR-based antiviral therapies

Company stage: Pre-clinical

Diseases (gene editing): HIV-1, influenza, SARS-CoV-2

Genome editing tool: CRISPR

Funding stage: Private

Location: Huddinge, Sweden

Website: https://www.biomedrex.com/index.html

Biomedrex Genetics is a start-up company that develops novel antiviral treatments based on the CRISPR-Cas system. The company aims to treat various infectious diseases, with HIV-1 being the lead viral target. The company is currently conducting pre-clinical testing.

Biomedrex Genetics

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Biomedrex Genetics

Search CRISPR Medicine